Table 5 Change in accompanying symptoms between TSC and placebo groups in the full analysis set (FAS)

2.50 ± 1.43

2.66 ± 1.47

0.1194

1.89 ± 1.32

2.38 ± 1.47

< 0.0001

1.34 ± 1.19

2.18 ± 1.49

< 0.0001

1.06 ± 1.10

2.21 ± 1.59

< 0.0001

0.77 ± 1.22

0.93 ± 1.33

0.0523

0.47 ± 0.97

0.83 ± 1.34

0.0002

0.31 ± 0.78

0.71 ± 1.29

< 0.0001

0.21 ± 0.70

0.79 ± 1.45

< 0.0001

0.98 ± 1.40

1.25 ± 1.58

0.0338

0.69 ± 1.17

0.97 ± 1.39

0.0029

0.48 ± 0.99

0.91 ± 1.39

< 0.0001

0.42 ± 0.88

0.95 ± 1.51

< 0.0001

0.67 ± 1.21

0.76 ± 1.31

0.3528

0.44 ± 0.96

0.63 ± 1.23

0.0278

0.34 ± 0.87

0.57 ± 1.19

0.0023

0.33 ± 0.83

0.61 ± 1.19

0.0002